Effect of Antacids (Mg-Al-based) on Imatinib Mesylate (Gleevec®) Pharmacokinetics in Healthy Volunteers (CSTI571BUS257)
Phase of Trial: Phase I
Latest Information Update: 25 Jan 2016
At a glance
- Drugs Imatinib (Primary) ; Aluminium hydroxide/magnesium hydroxide
- Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Dermatofibrosarcoma; Eosinophilia; Fibroma; Gastrointestinal stromal tumours; Malignant melanoma; Myelodysplastic syndromes; Polycythaemia vera; Prostate cancer; Sarcoma; Scleroderma; Systemic mastocytosis
- Focus Pharmacokinetics
- 08 Apr 2009 Actual end date changed from Dec 2007 to Oct 2008 as reported by ClinicalTrials.gov.
- 20 Dec 2007 Status changed from recruiting to completed.
- 03 May 2007 New trial record.